Kornimate/medical-research-clean huggingface dataset:
the effects of open versus closed kinetic chain exercises on ankle joint function

Conditions: Ankle Injuries

Summary: the goal of this randomized clinical trial is to find the effects of open versus closed kinetic chain exercises on ankle joint function in athletes with chronic ankle instability. the main question it aims to answer is: • to compare the effects of open versus closed kinetic chain exercises on pain, instability and balance in athletes with chronic ankle instability. participants were given consent form and after subjects read and signed the informed consent and completed the self-reported questionnaires designed to identify subjects with chronic ankle instability, subjects completed baseline measurements that included foot and ankle ability measure (faam)-sport subscale, reach distance, and sebt. participant were divided into two groups (group a and group b) through lottery method. group a received open kinetic exercises 3times a week for 3-4 weeks. group b received close kinetic exercises 3 times a week for 3-4 weeks.

chronic instability is a common condition in sports and there are many treatment methods and rehabilitation protocols available which are used according to extent of injury. the purpose of this study is to find out the effects of close kinetic chain exercises and open kinetic chain exercises and to find out which technique is more efficient for treating ankle instability, pain, and imbalance in athletes with chronic ankle instability. this study will help physical therapists and medical team to enhance the rehabilitation process. the study was randomized clinical trial conducted at pakistan sports board lahore in which convenient random sampling technique was used. this study included total 26 participants and for this purpose open epi tool would be used as a sample size calculation. participants falling in this category were recruited into the study after inclusion and exclusion criteria. the cumberland ankle instability tool was used as a tool for pre and post assessment of athletes. in this study we divided population into two groups. group a received open chain kinetic exercises and group b was treated with closed chain kinetic exercises. data was analyzed through spss 25 version.

Eligibility criteria:
inclusion criteria: * male * age 18-30years * tennis, football, cricketers, volley ball and hockey players * athletes with balance problems * chronic ankle injuries exclusion criteria: * acute injuries * non-athletes (minimum once a week sports participation) * athletes with pain related to calf muscles and achillies tendon
evaluating the safety, tolerability, and pharmacokinetics of biib095 in healthy participants

Conditions: Healthy Volunteer

Summary: the primary objective of the study is to evaluate the safety and tolerability of single- and multiple-ascending oral doses of biib095 in healthy participants. the secondary objectives are to characterize the single- and multiple-oral-dose pk of biib095 in healthy participants and to investigate the effect of food on the single-oral-dose pk of biib095 in healthy participants.


Eligibility criteria:
key inclusion criteria: * ability of the subject to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations. * must have a body mass index between 18 and 30 kg/m2, inclusive. * all women of childbearing potential and all men must practice highly effective contraception during the study and for 5 times the half-life or 3 months, whichever is longer, after their last dose of study treatment. in addition, subjects should not donate sperm or eggs during the study and for at least 3 months after their last dose of study treatment. * must be in good health as determined by the investigator, based on medical history and screening evaluations. key exclusion criteria: * history of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the investigator. * significant history of fainting or vaso-vagal attacks, as determined by the investigator. * current condition known to affect cardiac conduction, or a personal or familial history of brugada syndrome. * congenital nonhemolytic hyperbilirubinemia (gilbert's syndrome). * history or risk of seizures or a history of epilepsy, significant head injury or related neurological disorders (excluding childhood febrile convulsions), as determined by the investigator. * current enrollment in any other drug, biologic, device, or clinical study, or treatment with an investigational drug or approved therapy for investigational use within 30 days (6 months for biologics) prior to day -1, or 5 half-lives of the agent, whichever is longer. * exposure to more than 4 experimental chemical entities within 12 months prior to the first dosing day. * breastfeeding, pregnant, or planning to become pregnant during study participation note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: chronic pain neuropathic pain neuralgia healthy volunteers
multicentric study, three randomized arms (r-cvp vs r-chop vs r-fm),for patients with stage ii-iv follicular lymphoma

Conditions: Follicular Lymphoma

Summary: the purpose of this study is to define an improvement and theassessment of the time to treatment failure in patients randomized in three different arms: r-cvp vs r-chop vs r-fm.

assessment of overall survival (os)in patients treated with r-cvp, r-chop and r-fm. -assessment of progression free survival (pfs)in patients treated with r-cvp, r-chop - assessment of duration of response (dr)in patients treated with r-cvp, r-chop and r-fm. - assessment of response rate(rr) in patients treated with r-cvp, r-chop and r-fm. - assessment of molecular response rate in patients treated with r-cvp, r-chop and r-fm. - assessment of toxicity of r-cvp, r-chop, r-fm treatments.

Eligibility criteria:
inclusion criteria: 1. histological diagnosis of b cell follicular lymphoma 2. ecog performance status 0-2 3. age range 18-75 4. ann arbor stage: ii-iv 5. assessment of pathology with diagnostics biopsy 6. presence of one of these criteria: * b sistemic symptoms b * extranodale pathology * cytopenia * splenomegaly * leukemia * serous effusion * ves \> 20 mm/h * ldh \> normal value * nodale or extranodal mass \> 7 cm * 3 or more nodal sites \> 3 cm * adenopatic syndrome 7. lvef \> 50% 8. normal hepatic (bilirubin \ 1.5 mg/dl and of creatinin \> 2mg/dl 9. no previous treatment for follicolar lymphoma unless rt-if 10. lifetime \> 6 mounth 11. absence of hbsag, hcv e hiv 12. negative coombs test 13. negative pregnant test 14. cotracceptive method during the treatment and the follow three months 15. formal written consent 16. ability to follow the patients after the treatment for follow up exclusion criteria: 1. histological diagnosis of all type of lymphoma unless follicularlymphoma, cd20 lymphoma, stage iiib of follicular lymphoma and high degree lymphoma 2. stage i of ann arbor scale 3. central nervous system involvement 4. hiv, hbv or hcv positivity 5. cardiac pathology 6. positive coombs test 7. previous chemotherapeutic treatment 8. hypersensitivity to antibodyes or other murine proteins 9. previous cancer pathology unless in situ cervix and epithelial carcinomas 10. other type of infections 11. pregnant and nursing woman

Keywords: follicular lymphoma rituximab
clinical transcriptomics in systemic vasculitis (cutis)

Conditions: Cryoglobulinemic Vasculitis (CV); Drug-induced Vasculitis; Eosinophilic Granulomatosis With Polyangiitis (EGPA); IgA Vasculitis; Isolated Cutaneous Vasculitis; Granulomatosis With Polyangiitis (GPA); Microscopic Polyangiitis (MPA); Polyarteritis Nodosa (PAN); Urticarial Vasculitis; Vasculitis

Summary: multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.

this study employs a multi-center approach to evaluate cutaneous vasculitis across several forms of idiopathic vasculitis. patients with cutaneous manifestations of vasculitis will be evaluated by teams of primary vasculitis care providers and dermatologists in order to facilitate optimal selection of patients and sampling of lesions. a punch skin biopsy at a site of active vasculitis will be the source of material for histopathologic and transcriptomic evaluation. the histopathology of cutaneous vasculitis will be characterized using a standardized approach.

Eligibility criteria:
inclusion criteria: * have a cutaneous lesion (purpuric macules, palpable purpura, retiform purpura, nodules, ulcers, or urticarial) believed to be related to active vasculitis * have a suspected or confirmed diagnosis of: * cryoglobulinemic vasculitis (cv) * drug-induced vasculitis * eosinophilic granulomatosis with polyangiitis (egpa) * iga vasculitis * isolated cutaneous vasculitis * granulomatosis with polyangiitis (gpa) * microscopic polyangiitis (mpa) * polyarteritis nodosa (pan) * urticarial vasculitis * be willing and able to provide written informed consent (or assent for those under exclusion criteria: * you are less than five years old * considered not to be a candidate for a biopsy or have a higher risk of developing an infection, bleeding, etc., from the biopsy, or a doctor believes that the risks for you participating in this study do not outweigh the potential benefit of learning information from your biopsy * you have a neutrophil count (type of white blood cell) less than 1500/mm3, platelet count less than 50,000/mm3, or a hemoglobin less than 7 g/dl * you have an uncontrolled disease that could prevent you from completing the study procedures * you have an active infection at or near the potential biopsy site, have poor circulation, or have bony prominence or other structure that would increase your risk of complications if you participated in this study * you are pregnant or nursing * you are not able to provide informed consent

Keywords: div css egpa hsp gpa mpa pan wegeners
a study for japanese participants with rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: this study will evaluate the safety and tolerability of multiple doses of ly2127399 (tabalumab) in japanese participants with ra. the study consists of a 20-week treatment period. all participants will be followed for up to 12 weeks after the last study drug administration.


Eligibility criteria:
inclusion criteria: * have given written informed consent * women must not be pregnant, breastfeeding or be at risk to become pregnant during study participation * diagnosis of ra * active ra * current, regular use of methotrexate, at a stable dose * body weight between 40 and 105 kilograms (kg), inclusive exclusion criteria: * use of excluded medications (reviewed by study doctor) * have medical findings which, in the opinion of the study doctor, put participant at an unacceptable risk for participation in the study * have had recent or ongoing infection which, in the opinion of the study doctor put participant at an unacceptable risk for participation * evidence of tuberculosis * have systemic inflammatory condition other than ra
collection of the thrombo-vaxcov cohort

Conditions: Covid19; SARS-CoV Infection; Venous Thrombosis; Thrombocytopenia; Vaccination; Complications

Summary: in the context of anti-covid19 vaccination, atypical thrombosis have occured and potential link with vaccination is under investigation. this study collect clinical and biological data of all atypical thrombosis occurring within 4 weeks after anticovid vaccination.

in the context of anti-covid19 vaccination, atypical thrombosis have occurred and potential links with vaccination is under investigation. in france, the study collect clinical and biological data of all atypical thrombosis occurring within 4 weeks after anti-covid vaccination.

Eligibility criteria:
inclusion criteria: atypical thrombosis symptoms onset within 4 weeks of vaccination exclusion criteria: children
a clinical trial to compare the pharmacokinetics and tolerability of ckd-348

Conditions: Hypertension; Dyslipidemias

Summary: a clinical trial to compare the pharmacokinetics and tolerability of ckd-348

a randomized, open-label, single-dose, 3-way crossover clinical trial to compare the pharmacokinetics and tolerability of ckd-348 with co-administrated drugs in healthy adult volunteers

Eligibility criteria:
inclusion criteria: 1. healthy adult volunteers aged ≥ 19-year-old 2. weight ≥ 50kg (man) or 45kg (woman), with calculated body mass index(bmi) of 18 to 30 kg/m2 3. those who are eligible for adequate blood pressure criteria during screening tests systolic blood pressure: 90 to 139 mmhg diastolic blood pressure: 60 to 89 mmhg 4. those who have no congenital chronic disease or chronic disease requiring treatment and who have no pathological symptoms or findings 5. those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serum, urine test) and 12-lead ecg results during screening tests 6. those who agree to contraception during the participation of clinical trial 7. those who voluntarily decide to participate and agree to comply with the cautions after hearing and fully understanding the detailed description of this clinical trial exclusion criteria: 1. those who received investigational product or bioequivalence test drug within 6 months before the first administration of clinical trial drug 2. those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 1 month before the first administration of clinical trial drug 3. those who donated whole blood and apheresis within 2 months or received transfusion within 1 month 4. those who has a history of gastrointestinal surgery ( 5. those who exceeding an alcohol and smoke consumption criteria alcohol: men - 21 glass/week, women - 14 glass/week (1 glass: soju 50 ml, beer 250ml, wine 30ml) smoke: 20 cigarettes/day 6. those who has a disease history of diabetic mellitus, nephropathy, biliary obstruction, shock, dihydropyridine sensitivity, angioedema, cardiac insufficiency 7. genetic problems such as galactose intolerance, lapp lactose deficiency or glucose-galactose malabsorption 8. those who are deemed unfit by the investigators to participate in the clinical trial for other reasons including the results of laboratory tests 9. women who are pregnant or who may be pregnant and breastfeed

Keywords: ckd-348
the relationship between psychological factors and bell's palsy

Conditions: Bell's Palsy

Summary: the aim of this study was to explore the risk factors for bell's palsy (bp) and to examine whether psychological factors are the potential risk factors for the occurrence of bp.

we conducted a case-control, multi-center clinical investigation. a total of 695 subjects were assigned to the case group (n=355) and the control group (n=340). all the bp patients were enrolled from 11 state hospitals in china, and all the controls were selected from the same district to match for the patients. the study was coordinated by a tertiary referral centre, tongji hospital. the house-brackmann grading system and facial disability index (fdi) was adopted to assess the bp patients. kessler 10-item psychological distress scale（k10）was usde to explore the psychological distress, and the cattell 16 personality factor (16pf) scale was employed to evaluate the personality profiles of all subjects.

Eligibility criteria:
inclusion criteria: 1. patients who were diagnosed to have unilateral facial-nerve weakness without any identifiable causes within 168 hours after onset of symptoms; 2. aged 18 to 65 years. exclusion criteria： 1. illiterate; 2. the facial paralysis is caused by herpes zoster; 3. recurrent facial paralysis; 4. noticeable asymmetry of the face before the illness which may affect the evaluation; 5. history of peptic ulcer disease, severe hypertension, uncontrolled diabetes, liver and kidney dysfunction, pregnancy, mental illness, or serious systemic diseases which may affect the treatment.

Keywords: bell's palsy psychological stress personality factors psychological factors
a study to investigate drug-drug interaction between d326, d337 and ckd-828 in healthy subjects

Conditions: Dyslipidemias; Hypertension

Summary: to evaluate pharmacokinetic properties and drug interactions between d326 and d337 co-administered groups, the ckd-828 alone and the total co-administered groups.


Eligibility criteria:
inclusion criteria: 1. healthy volunteers aged between ≥ 19 and ≤ 40 years old 2. calculated body mass index(bmi) of ≥ 19 and ≤ 28kg/m² 3. subject who agree to use a combination of effective contraceptive methods or medically acceptable contraceptive methods from the date of first administration of investigational product until completion of the clinical trial 4. subject who agree not to provide sperm 5. subject who voluntarily agree to participate in this study exclusion criteria: 1. any medical history that may affect drug absorption, distribution, metabolism and excretion 2. subject who has a clinically significant disease or history such as endocrine, gastrointestinal, cardiovascular, muscular disease. 3. genetic problems such as galactose intolerance, lapp lactose dehydrogenase deficiency or glucose-galactose uptake disorder 4. subject who have received other clinical trial drugs within 90 days prior to the screening visit 5. any clinically significant active chronic disease

Keywords: dyslipidemias hypertension drug-drug interaction
tariquidar-ondansetron combination in neuropathic pain

Conditions: Neuropathic Pain

Summary: prospective, randomized, double-blind, placebo controlled, cross-over proof of concept study. to determine the pharmacokinetics and tolerability of co-administration of 5-ht3r antagonist ondansetron with a p-glycoprotein inhibitor tariquidar, in patients with neuropathic pain.

the investigators hypothesize that co-administration of a 5-ht3 receptor antagonist ondansetron (single 16mg dose) with p-glycoprotein inhibitor tariquidar (single 4mg/kg dose) vs placebo in a cross-over prospective randomized study, will: 1. be tolerable in patients with neuropathic pain. 2. increase the cerebrospinal fluid (csf) to plasma ratio of ondansetron after intravenous administration, compare to ondansetron alone 3. result in a greater reduction in pain intensity than with ondansetron alone.

Eligibility criteria:
inclusion criteria: 1. age 18-65; 2. documented diagnosis of neuropathic pain due to damage or disease affecting the peripheral nervous system; 3. at least probable neuropathic pain grading1; 4. pain duration \>3 months; 5. average pain intensity ≥4 on 0-10 numerical rating scale (nrs). exclusion criteria: 1. current pregnancy or lactation; 2. moderate-severe kidney or liver dysfunction; 3. active cardiac arrhythmias (non-sinus rhythm), long qt syndrome, or qtc interval \>450msec; 4. congestive heart failure 5. abnormal troponin values at screening visit; 6. current treatment with mao inhibitors, mirtazapine, ssri antidepressants, or snri medications duloxetine or venlafaxine; 7. current treatment with tapentadol, tramadol, or fentanyl; 8. current treatment with p-glycoprotein substrate drugs with narrow therapeutic window, e.g. digoxin; 9. current treatment with tricyclic antidepressant medications (e.g. amitriptyline, desipramine, imipramine) at a dose \>25mg/day; 10. ongoing use of any of the following medications with known effects on pgp function: carbamazepine, phenytoin, phenobarbital, cyclosporine, clarithromycin, erythromycin, ritonavir, verapamil, rifampicin, st. john's wort; 11. current treatment with qt-prolonging drugs, and drugs known to have a significant interaction with ondansetron or other p-glycoprotein substrates (see section 2.3.3.); 12. current treatment with anticoagulant drugs;
safety and efficacy assessment treatment trials of emixustat hydrochloride

Conditions: Geographic Atrophy

Summary: the purpose of this study is to determine if emixustat hydrochloride (acu-4429) reduces the rate of progression of geographic atrophy compared to placebo in subjects with dry age-related macular degeneration.


Eligibility criteria:
inclusion criteria: 1. males or females, age ≥55 years. 2. clinical diagnosis of ga associated with amd 3. able and willing to provide written informed consent. 4. able to reliably administer oral medication by self or with available assistance. exclusion criteria: 1. active cnv or presence of an active ocular disease. 2. known serious allergy to the fluorescein sodium for injection in angiography. 3. pre-specified laboratory abnormalities at screening. 4. treatment with any investigational study drug within 30 days of screening or device (within 60 days of screening) 5. history of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding 6. female subjects who are pregnant or lactating. 7. female subjects of childbearing potential and male subjects who are not surgically sterile who are not willing to practice a medically accepted method of birth control from screening through 30 days after completion of the study. 8. unstable or poorly controlled medical or ophthalmic conditions

Keywords: geographic atrophy ga dry amd